ZIVO Bioscience (OTCMKTS:ZIVO) Shares Cross Below Fifty Day Moving Average of $3.22

ZIVO Bioscience, Inc. (OTCMKTS:ZIVOGet Rating) passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $3.22 and traded as low as $2.93. ZIVO Bioscience shares last traded at $3.18, with a volume of 5,524 shares traded.

The stock has a 50-day moving average of $3.22 and a 200 day moving average of $3.27.

ZIVO Bioscience (OTCMKTS:ZIVOGet Rating) last released its quarterly earnings results on Friday, May 13th. The biotechnology company reported ($0.22) EPS for the quarter.

A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in ZIVO Bioscience by 19.6% during the 1st quarter. Vanguard Group Inc. now owns 92,468 shares of the biotechnology company’s stock worth $359,000 after buying an additional 15,147 shares in the last quarter. Credit Suisse AG acquired a new position in ZIVO Bioscience during the 3rd quarter worth $206,000. Finally, Two Sigma Securities LLC acquired a new position in ZIVO Bioscience during the 3rd quarter worth $138,000. 5.54% of the stock is currently owned by hedge funds and other institutional investors.

About ZIVO Bioscience (OTCMKTS:ZIVO)

ZIVO Bioscience, Inc, a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. It operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health.

Further Reading

Receive News & Ratings for ZIVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.